ChemoCentryx Issues Top-Line Interim Results for CCX140, Says Data Showed Statistically Significant Reduction in Protein

ChemoCentryx, Inc.(Nasdaq: CCXI) today announced interim data from an ongoing Phase II study inpatients with diabetic nephropathy, also known as diabetic kidney disease,with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2,and the drug candidate is wholly owned by the Company. Examining data throughthe first 12 weeks of dosing in the ongoing 52 week trial, in which CCX140 isadded on top of the standard of care for diabetic nephropathy patients (i.e.,stable doses of angiotensin pathway inhibitors), the drug candidate appearswell-tolerated in the patient population to date. The safety observations wereconsistent with a concurrent analysis by the Company's independent safety datamonitoring committee, which independently assessed the interim data andrecommended no changes to the ongoing study protocol. In addition, data alsoshowed that patients treated with 5 mg CCX140 once daily experienced astatistically significant reduction of protein in the urine, or proteinuria,as measured by Urinary Albumin Creatinine Ratio (UACR) versus those patientsreceiving only the standard of care (placebo group), following two weeks oftreatment (total study number, n, analyzed at that time point = 332; p